Continuing participation supports ultrasound screening for ovarian cancer

E. J. Pavlik, T. L. Johnson, P. D. Depriest, M. A. Andrykowski, R. J. Kryscio, J. R. Van Nagell

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The effect of ovarian cancer screening on survival is enabled by women who continue to actively participate in screening. In this report, factors that affect participation are examined. Participants included 13 963 Kentucky women who received 56 392 screens accounting for a 46 113 screening year experience. Background, health history and reasons for participating in transvaginal sonographic screening were collected via a self-reported questionnaire. Screening participants were characterized as > 50 years old, mostly married, well educated, medically insured, health conscious women, living in the vicinity of the screening centre or 51-150 miles away. Approximately 70% of the participants can be considered active in the study based upon a screening visit during the 1997-1998 2-year period. The probabilities of a return screen at 1, 2, 5 and 7.5 years were 77.8%, 72.0%, 58.7% and 50.6%, respectively. A total of 96% of return visits occurred within 2 years, with 33.7% having intervals of < 1 year. Perceived family history was not observed to affect continuation. However, abnormal findings were associated with a shortened participation. These high levels of continuation in ultrasound screening indicate that women take this disease seriously and demonstrate that this disease is of consequence to them.

Original languageEnglish
Pages (from-to)354-364
Number of pages11
JournalUltrasound in Obstetrics and Gynecology
Issue number5
StatePublished - 2000


  • Cancer
  • Ovary
  • Participation
  • Screening
  • Ultrasound

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Reproductive Medicine
  • Radiology Nuclear Medicine and imaging
  • Obstetrics and Gynecology


Dive into the research topics of 'Continuing participation supports ultrasound screening for ovarian cancer'. Together they form a unique fingerprint.

Cite this